These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3127216)

  • 21. Silent renal microangiography after mitomycin C therapy.
    Poch E; González-Clemente JM; Torras A; Darnell A; Botey A; Revert L
    Am J Nephrol; 1990; 10(6):514-7. PubMed ID: 2127509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitomycin-induced hemolytic-uremic syndrome. Successful treatment with corticosteroids and intense plasma exchange.
    Lyman NW; Michaelson R; Viscuso RL; Winn R; Mulgaonakar S; Jacobs MG
    Arch Intern Med; 1983 Aug; 143(8):1617-8. PubMed ID: 6870446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-induced nephropathy: our recent clinical experience.
    Omata M; Kikuchi M; Higuchi C; Sanaka S; Takuma T; Sugino N; Mori Y
    Dev Toxicol Environ Sci; 1986; 14():15-20. PubMed ID: 3104006
    [No Abstract]   [Full Text] [Related]  

  • 24. Mitomycin-induced hemolytic-uremic syndrome.
    Proia AD; Harden EA; Silberman HR
    Arch Pathol Lab Med; 1984 Dec; 108(12):959-62. PubMed ID: 6210069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma.
    Crocker J; Jones EL
    J Clin Pathol; 1983 Jan; 36(1):24-9. PubMed ID: 6401771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mytomycin C nephrotoxicity. 3 new cases and review of the literature].
    Simon P; Hervé JP; Ramée MP; Leroy JP; Ang KS; Leguy P; Vignoud J; Cledes J
    Nephrologie; 1982; 3(4):152-7. PubMed ID: 6818483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of mitomycin C nephropathy.
    Motoo Y; Sawabu N; Ikeda K; Takemori Y; Ohta H; Okai T; Yokoyama H
    Intern Med; 1994 Mar; 33(3):180-4. PubMed ID: 8061399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitomycin C-induced pulmonary and renal toxicities.
    Loprinzi CL
    Wis Med J; 1984 Mar; 83(3):16-7. PubMed ID: 6428065
    [No Abstract]   [Full Text] [Related]  

  • 29. [Mitomycin C associated hemolytic uremic syndrome--a case report and review of the Japanese cases].
    Shirakawa K; Morita S; Tojo M; Tsuda M; Uchida R; Mimoto H; Hatamori N; Okabayashi Y; Saeki S; Oimomi M
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):2057-61. PubMed ID: 8215482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary angiomatoid vascular changes in mitomycin C-associated hemolytic-uremic syndrome.
    Chang-Poon VY; Hwang WS; Wong A; Berry J; Klassen J; Poon MC
    Arch Pathol Lab Med; 1985 Sep; 109(9):877-8. PubMed ID: 3927871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two patients suffering from interstitial pneumonitis and haemolytic-uraemic syndrome as side effects of mitomycin C therapy.
    van Spreeuwel JP; Hemrika MH; de Maat CE; Nadorp JH
    Neth J Med; 1983; 26(9):287-8. PubMed ID: 6419134
    [No Abstract]   [Full Text] [Related]  

  • 32. Hemolytic-uremic syndrome in a patient receiving mitomycin C and 5-fluorouracil.
    Willie GR; Levy SM; Michaels RS; Zirkin RM
    Henry Ford Hosp Med J; 1983; 31(2):104-9. PubMed ID: 6313552
    [No Abstract]   [Full Text] [Related]  

  • 33. Mitomycin-C induced hemolytic uremic syndrome: a case report and literature review.
    Wu DC; Liu JM; Chen YM; Yang S; Liu SM; Chen LT; Whang-Peng J
    Jpn J Clin Oncol; 1997 Apr; 27(2):115-8. PubMed ID: 9152802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.
    Cantrell JE; Phillips TM; Schein PS
    J Clin Oncol; 1985 May; 3(5):723-34. PubMed ID: 3923162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experience of a combination chemotherapy consisting of 5-FU, MMC, and FT-207--side effects against kidney].
    Yamada F; Kagami H; Fukutome A; Mastumine T; Miura T
    Gan To Kagaku Ryoho; 1983 Sep; 10(9):2049-54. PubMed ID: 6412636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitomycin-induced hemolytic uremic syndrome: case presentation and review of literature.
    Rabadi SJ; Khandekar JD; Miller HJ
    Cancer Treat Rep; 1982 May; 66(5):1244-7. PubMed ID: 7083229
    [No Abstract]   [Full Text] [Related]  

  • 37. Hemolytic-uremic syndrome and acute renal failure in metastatic adenocarcinoma treated with mitomycin: case report and literature review.
    D'Elia JA; Aslani M; Schermer S; Cloud L; Bothe A; Dzik W
    Ren Fail; 1987; 10(2):107-13. PubMed ID: 3120247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Side effects and anti-cancer effects following intraperitoneal (ip) administration of mitomycin C (MMC)].
    Takizawa K; Ino Y; Isono T; Sato M; Iguchi T; Takeda Y
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1877-83. PubMed ID: 3109329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of mitomycin-C-associated hemolytic uremic syndrome with plasmapheresis.
    Poch E; Almirall J; Nicolas JM; Torras A; Revert L
    Nephron; 1990; 55(1):89-90. PubMed ID: 2112726
    [No Abstract]   [Full Text] [Related]  

  • 40. 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
    van der Gaast A; Verweij J; Planting AS; Stoter G
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):765-8. PubMed ID: 3383976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.